Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States (Q43667321)
Jump to navigation
Jump to search
scientific article published on 12 March 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States |
scientific article published on 12 March 2012 |
Statements
1 reference
Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States (English)
1 reference
Anne-Laure Guillermin
1 reference
Adam Lloyd
1 reference
Jennie H Best
1 reference
Mary Beth DeYoung
1 reference
Yevgeniy Samyshkin
1 reference
Julia Aledort Gaebler
1 reference
12 March 2012
1 reference
1 reference
15
1 reference
4
1 reference
654-663
1 reference
Identifiers
1 reference
1 reference